2.8.24 – Flu Prebook Now Open for All Flu Manufacturers
Access Vaccines members receive member discounts on all brands of prebooked doses of flu. All manufacturers of flu are now available to prebook. To ensure member pricing, please contact Access Vaccines if your clinic is purchasing a new brand of flu for the first time or switching brands from last year. Access Vaccines members will receive the best possible price and terms on flu for prebooked doses.
- Sanofi: Fluzone, Flublok, Fluzone HD
- GSK: Fluarix, Flulaval
- Seqirus: Flucelvax, Afluria, Fluad
- FluMist by AstraZeneca
2.2.24 – First Ever Covid-19 and Flu Test: Lucira by Pfizer
Groundbreaking lab technology provides fast results for patients during their visit. One test, two results. Access Vaccines members will now have the opportunity to purchase this new, groundbreaking test by Pfizer at discounted member rates. Lucira by Pfizer is the first and only test for both Covid-19 and Flu A + B. Combined testing device for fast, accurate, point-of-care testing powered by molecular technology. Test results in 30 minutes or less.
- First and only for Covid-19 and Flu A + B
- Discounts Available for AV Members
- Test costs are Reimbursable
- Convenient 3-in-1 testing
1.24.24 – Sanofi’s Groundbreaking Infant RSV Vaccine: Beyfortus is Now Back in Stock and Available at Discount Member Pricing for Access Vaccines Members
Supply issues eased: CDC resumes routine recommendations for Nirsevimab (Beyfortus) to protect infants and high-risk toddlers from severe RSV. On January 5, 2024 CDC issued a Clinician Outreach and Communicaiton Activity (COCA) emergency alert: Updated Guidance for Healthcare Providers on Increased Supply of Nirsevimab to Protect Young Children from Severe Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season. CDC now recommends resuming adherence to the published ACIP recommendations for use of nirsevimab and provides considerations for individual facilities with limited supplies. Immunize.org is updating its standing orders template to reflect this change.
1.2.24 – Acccess Vaccines Merck Discount Program Provides Access Vaccines Members the Lowest National Price on Gardasil
Access Vaccines offers the lowest national price on Gardasil through the Merck Discount Program. The exclusive program provides members will discounts on Gardasil, Rotateq and all other Merck Vaccines.
- Lowest National Price on Gardasil
- Lowest National Price on Rotateq
- Discounts on all Merck Vaccines
12.20.23 – Peak Season for Respiratory Approaching: Study Reveals Co-Administered Covid-19 and Flu Vaccines Effective, Especially in Seniors
In a recent study published in JAMA Network Open, researchers evaluate the effectiveness of coadministering the Pfizer-BioNTech BNT162b2 BA.4/5 bivalent coronavirus disease 2019 (COVID-19) vaccine and seasonal influenza vaccines (SIVs) as compared to administering each vaccine separately in a community setting.
COVID-19 hospitalizations are rising quickly. Since the summer, public health officials have been tracking a rise in multisystem inflammatory syndrome in children (MIS-C), which is caused by COVID-19. Influenza activity is growing in most parts of the country. RSV activity remains high in many areas. In some parts of the country, hospital beds for children are already nearly as full as they were this time last year. If these trends continue, the situation at the end of this month could again strain emergency departments and hospitals. Strain on the healthcare system could mean that patients with other serious health conditions may face delays in receiving care.
Members of Access Vaccines can safeguard patients during the upcoming high-risk respiratory disease season by participating in and leveraging Access Vaccines Discount Programs for both Covid and Flu Vaccines.
12.14.23 – Annual Manufacturer Price Increases Coming Soon, Start 2024 with 2023 Pricing
GSK and Sanofi’s annual price increases are coming at the beginning of the year. This is a good time for Access Vaccines members to take advantage of 2023 pricing before the price increases take effect.
- GSK Portfolio and Rotarix Tier Members: Price Increase goes into affect: 2/1/2024
- GSK Bexsero Only Members: No price increase, 2023 price frozen for 2024
- Sanofi Members (all discount programs): Price Increase goes into affect: 1/1/2024
- GSK: Last day to order is 12/20/2023 by 3pm Easterm, Shipping resumes: 1/3/2023
- Sanofi: No shipping 12/25/2023 and 12/29/2023 – 1/2/2023, Shipping resumes: 1/3/2023
11.14.23 – Pfizer’s 12+ yrs Covid Vaccine Now Available at Lowest National Price for Access Vaccines Members in “Never Frozen” Glass Prefilled Syringes
The FDA issued an update to the dosage and administration section of the COMIRNATY (COVID-19 Vaccine, mRNA) USPI to include COMIRNATY Single Dose Glass Prefilled Syringes. In addition to the previously included plastic prefilled syringe and Single Dose Vial presentations for individual 12 years of age and older, the USPI now includes (NDC 0069-2377-10, carton of 10 single dose prefilled syringes; NDC 0069-2377-01, single dose prefilled syringe). The glass prefilled syringes have never been frozen and will be available mid-November through wholesalers.
These glass prefilled syringes were developed to be stored in a refrigerator and are “NEVER FROZEN”, have never been frozen, and must be stored at 2°C to 8°C (35°F to 46°F) until the expiration date printed on the carton and syringe labels. DO NOT FREEZE.
- Product expiration is 6 months from when it was manufactured.
- The expiration of the product will be on the box and customers will use this date versus the need to relabel with prior product
- DO NOT FREEZE will be listed on the carton and highlighted in Pink
10.24.23 – US FDA Gave Thumbs-up to Penbraya, Pfizer’s Pentavalent Vaccine Reducing Shot Count to Protect Against Meningococcal Disease
Defending against the most common serogroups behind meningococcal disease. The shot is approved for adolescents and adults between the ages of 10 and 25. Penbraya mixes components from two of the company’s other meningococcal vaccines – Trumenba and Nimenrix – which together tackle serogroups A, B, C, W and Y. These serogroups account for nearly all invasive meningococcal disease. Prior to Pfizer’s Penbraya approval, protection from all five groups required four injections from two separate vaccines.
10.19.23 – CDC Recommends Pfizer or Sanofi RSV Vaccine to Provide Protection Against Infant RSV
ACIP and CDC recommended RSVpreF vaccine using seasonal administration (i.e., during September through end of January in most of the continental United States) for pregnant persons as a one-time dose at 32–36 weeks’ gestation for prevention of RSV-associated LRTI in infants aged <6 months. Either maternal RSVpreF vaccination during pregnancy or nirsevimab administration to the infant is recommended to prevent RSV-associated LRTI among infants, but both are not needed for most infants. All infants should be protected against RSV-associated LRTI through use of one of these products.
10.12.23 – Pfizer’s RSV Vaccine Abrysvo Recommended by the American College of Obstetricians – Study Published
The American College of Obstetricians and Gynecologists (ACOG) recommends a single dose of Pfizer’s RSV vaccine (Abrysvo) for pregnant individuals between 32 0/7 and 36 6/7 weeks of gestation, using seasonal administration, to prevent RSV lower respiratory tract infection in infants. For most of the United States, RSV season occurs from September through January. As such, similar to seasonal influenza vaccination, RSV vaccination is recommended for pregnant individuals during the months of September through January. The CDC’s Advisory Committee on Immunization Practices (ACIP) voted to recommend a single dose of maternal RSV vaccination for pregnant people at 32 through 36 weeks of gestation.
10.4.23 – Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in US
The U.S. Food and Drug Administration said on Tuesday it authorized an updated version of Novavax’s (NVAX.O) COVID-19 vaccine for emergency use in individuals aged 12 years and older. “ACIP’s recommendation last month, which was then approved by the CDC director, was inclusive of all FDA-licensed or authorized updated COVID-19 vaccines including those expected to be licensed or authorized in the coming months,” the spokesperson added. Novavax, whose protein-based shot uses a technology employed for decades to combat diseases, missed out on the pandemic vaccine windfall enjoyed by mRNA rivals due to manufacturing issues that delayed filing for approval when COVID was raging.
9.22.23 – Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO for RSV
Pfizer Inc. (NYSE: PFE) shared today it has broadened its portfolio of respiratory vaccines recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) following a favorable vote for ABRYSVO™ [Respiratory Syncytial Virus Vaccine], the company’s bivalent RSV prefusion F (RSVpreF) vaccine, as a maternal immunization. This is the first-ever fall in which eligible individuals can receive Pfizer vaccines to help protect against RSV, COVID-19, and pneumococcal pneumonia.
- ABRYSVO recommended by CDC Advisory Committee for pregnant persons 32 through 36 weeks gestation to help protect infants from respiratory syncytial virus (RSV) from birth through first six months of life
- RSV maternal immunization recommendation adds to Pfizer’s respiratory vaccines offerings already available to help protect against RSV in older adults, COVID-19, and pneumococcal pneumonia in adults
9.12.23 – Pfizer, Moderna score FDA nods for next round of seasonal COVID-19 vaccines
Out with the old and in with the new: Monday, the US FDA approved retooled mRNA shots against COVID-19 from Pfizer-BioNTech and Moderna simultaneously bidding adieu to the companies’ bivalent shots in the US. The FDA has approved Pfizer-BioNTech and Moderna’s separate vaccine formulations that are more closely targeted to current variants of the disease, the agency said in a release. The vaccines have been updated to include a monovalent component aimed at omicron variant XBB.15, according to the companies and the FDA. Meanwhile, Novavax’s revised shot is still pending regulatory approval.
8.31.23 – GSK’s RSV Arexvy: RSV Vaccines Remains Effective Against Distinct Viral Variants
GSK’s Arexvy vaccine for respiratory syncytial virus (RSV) — the first to be approved for older adults — can remain effective against a range of variants and produces strong antibody responses against distinct viral strains, according to a new study. The study results, published in the journal Science Translational Medicine, indicate that the vaccine could offer enduring protection against both contemporary RSV and future variants, especially when combined with vaccine adjuvants.
8.28.23 – US CDC Advisory Committee unanimously recommends routine use of Beyfortus (nirsevimab) to protect infants against RSV
CDC is recommending a new immunization starting this fall to help protect all infants under 8 months and some older babies at increased risk of severe illness caused by respiratory syncytial virus (RSV).
Today, CDC director Mandy Cohen, MD, MPH, adopted the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation for the use of nirsevimab, trade name BeyfortusTM, a long-acting monoclonal antibody product, which has been shown to reduce the risk of both hospitalizations and healthcare visits for RSV in infants by about 80 percent.
8.22.23 – FDA Approves Pfizer’s Abrysvo for Pregnancy to Protect Babies
Already with an approval in hand for older adults, Pfizer’s Abrysvo has become the first vaccine for pregnant women to protect their newborns against respiratory syncytial virus (RSV). The FDA has signed off on Abrysvo for women who have been pregnant for 32-36 weeks. The shot affords protection to babies for the first six months of their lives.
8.1.23 – Quest Launches Blood Test for Alzheimer’s Disease
Advances in drug treatment for Alzheimer’s disease have opened doors for diagnostics, and Quest is the latest to walk through. The clinical testing giants has put forward a blood test designed to help gauge a person’s level of beta amyloid – one of the hallmarks of neurodegenerative condition – and it’s now making it available directly to consumers.
6.25.23 – FDA Advisory Committee Recommends a Monovalent COVID booster
FDA Advisory committee, which decided unanimously that COVID vaccines this fall should not provide coverage against the original, wild-type coronavirus and that protection is only needed against an XBB strain. The advisory committee recommendation is consistent with a directive last month from the World Health Organization, which has recommended that the new COVID-19 boosters target XBB subvariants.
6.15.23 – FDA Advisory Committee unanimously recommends Nirsevimab as first immunization against RSV for all infants
About RSV: RSV is a very contagious virus that can lead to serious respiratory illness for infants, according to the Centers for Disease Control and Prevention (CDC). RSV symptoms can include runny nose, coughing, sneezing, fever, decrease in appetite, and wheezing.1 Two out of three infants are infected with RSV during their first year of life and almost all infants are infected by their second birthday.1,2 In the U.S., RSV is the leading cause of hospitalization in infants under 12 months, averaging 16 times higher than the annual rate for influenza.3,4 Approximately 75% of infants hospitalized for RSV are born healthy and at term with no underlying conditions.5 Each year in the U.S., there are an estimated 590,000 RSV disease cases in infants under one requiring medical care, including physician office, urgent care, emergency room visits and hospitalizations.6
5.19.23 – U.S. FDA Approves Prevnar 20, Pfizer’s 20 Valent Pneumococcal Conjugate Vaccine For Infants And Children
Pfizer Inc. announced on April 27th that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20®(20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through five years of age caused by the original seven serotypes contained in PREVNAR®.
“Today’s FDA approval of our vaccine, PREVNAR 20, now offers parents the ability to help protect their children against 20 pneumococcal serotypes in circulation, which represent the majority of pneumococcal disease in U.S. infants and children,”1,2 said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer. “This important PREVNAR 20 approval builds on more than 20 years of real-world impact with PREVNAR and PREVNAR 13, safety data, and effectiveness; highlighting Pfizer’s leadership in developing groundbreaking pneumococcal conjugate vaccines to help protect infants and their families from life threatening infections. We are grateful to the families and clinical investigators who participated in this research and our colleagues who have worked tirelessly to develop this breakthrough vaccine.”